CytoDyn Inc.
CYDY- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001175680
No open-market purchases or sales by CytoDyn Inc. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $35.2K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding CytoDyn Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 21 | 20 | −1 |
| Shares | 782.5K | 837.9K | +55.5K (+7.1%) |
| Value | $2.11M | $1.43M | −$681.0K (−32.2%) |
New holders (5)
Institutions that held CytoDyn Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Capital Advantage, Inc. | 91,000 | $155.0K | 0.04% |
| Willis Investment Counsel | 87,237 | $148.0K | 0.01% |
| MAI Capital Management | 25,000 | $43.0K | 0.00% |
| Holloway Wealth Management, LLC | – | $6.00K | 0.00% |
| Tradition Wealth Management, LLC | 2,697 | $5.00K | 0.00% |
Sold out (6)
Institutions that held CytoDyn Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Next Capital Management LLC | 37,500 | $101.0K |
| Livingston Group Asset Management CO (operating as Southport Capital Management) | 17,000 | $46.0K |
| Auxier Asset Management | 14,300 | $39.0K |
| Taylor Wealth Management Partners | 11,950 | $32.0K |
| Crescent Capital Consulting, LLC | 225 | $1.00K |
| FNY Investment Advisers, LLC | 200 | $0 |